Table 1.
Summary of baseline characteristics
| Covariate | Levels | Frequency (percent) |
|---|---|---|
| Race | Caucasian | 40(66.7%) |
| Other | 20(33.3%) | |
| Gender | Female | 22(36.7%) |
| Male | 38(63.3%) | |
| ECOG PS | 0 | 16(26.7%) |
| 1 | 42(70%) | |
| 2 | 2(3.3%) | |
| Siewert classification | Type 3 GEJ | 29(48.3%) |
| Gastric | 31(51.7%) | |
| Baseline EUS T | T2 | 5(8.3%) |
| T3/T4 | 55(91.7%) | |
| Baseline EUS N | N0 | 27(45%) |
| N1/N2 | 33(55%) | |
| Baseline M | M0 | 60(100%) |
| Baseline Clinical Stage | I/II | 26(43.3%) |
| III/IV | 34(56.7%) | |
| Presence of Signet ring cells (SRC) | Yes | 31(51.6%) |
| No | 29(48.3%) | |
| Histologic Grade | G2-Moderately differentiated | 17(28.3%) |
| G3-Poorly differentiated | 43(71.7%) | |
| iSUV | ≤6 | 30(50%) |
| >6 | 30(50%) | |
| Tumor Size | N/A-Not available | 18(.%) |
| <5 | 18(42.9%) | |
| ≥5 | 24(57.1%) |